RCAG
ESPR

Rehmann Capital Advisory Group’s Esperion Therapeutics ESPR Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$77.4K Hold
2,111
– – 0.01% 513
2019
Q2 		$98.2K Hold
2,111
– – 0.01% 618
2019
Q1 		$84.8K Hold
2,111
– – 0.01% 644
2018
Q4 		$97.1K Buy
+2,111
New +$102K 0.01% 409

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Rehmann Capital Advisory Group's ESPR Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Esperion Therapeutics (ESPR) position steady in Q3 2019 at 2,111 shares worth $77.4K. The position accounts for 0.01% of the portfolio, ranked #513.

Rehmann Capital Advisory Group first reported a position in ESPR in Q4 2018 and has held it in 4 quarters since. The position peaked at $98.2K in Q2 2019. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

  • Rehmann Capital Advisory Group held 2,111 shares of Esperion Therapeutics worth $77.4K as of Q3 2019.
  • Rehmann Capital Advisory Group left its Esperion Therapeutics share count unchanged in Q3 2019.
  • Esperion Therapeutics made up 0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #513 holding.
  • Rehmann Capital Advisory Group first reported a position in Esperion Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Rehmann Capital Advisory Group's Esperion Therapeutics position peaked at $98.2K in Q2 2019.
  • 152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.